In the past week, CVAC stock has gone up by 13.93%, with a monthly gain of 28.67% and a quarterly plunge of -2.90%. The volatility ratio for the week is 7.52%, and the volatility levels for the last 30 days are 6.92% for CureVac N.V The simple moving average for the past 20 days is 15.91% for CVAC’s stock, with a 15.01% simple moving average for the past 200 days.
Is It Worth Investing in CureVac N.V (NASDAQ: CVAC) Right Now?
CureVac N.V (NASDAQ: CVAC) has a price-to-earnings ratio that is above its average at 4.58x. The stock has a 36-month beta value of 2.43. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CVAC is 93.99M, and at present, short sellers hold a 5.10% of that float. On May 02, 2025, the average trading volume of CVAC was 631.27K shares.
CVAC) stock’s latest price update
The stock price of CureVac N.V (NASDAQ: CVAC) has jumped by 8.24 compared to previous close of 3.40. Despite this, the company has seen a gain of 13.93% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-10 that CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih – Vice President, Corporate Communications and Investor Relations Alexander Zehnder – Chief Executive Officer Myriam Mendila – Chief Scientific Officer Axel Sven Malkomes – Chief Financial Officer Conference Call Participants Alec Stranahan – Bank of America Ryan McElroy – Leerink Partners Roger Song – Jefferies Jasmine Fels – UBS Roy Buchanan – Citizens JMP Jonathan Miller – Evercore ISI Chiara Montironi – Kempen Operator Greetings.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the previous year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at 19.41% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.30% of loss for the given period.
Volatility was left at 6.92%, however, over the last 30 days, the volatility rate increased by 7.52%, as shares surge +29.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.89% upper at present.
During the last 5 trading sessions, CVAC rose by +13.62%, which changed the moving average for the period of 200-days by +3.09% in comparison to the 20-day moving average, which settled at $3.17. In addition, CureVac N.V saw 7.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Myriam Mendila, who proposed sale 17,839 shares at the price of $4.93 back on Jan 07 ’25. After this action, Myriam Mendila now owns shares of CureVac N.V, valued at $88,019 using the latest closing price.
Pierre Kemula, the affiliate of CureVac N.V, proposed sale 51,523 shares at $4.93 during a trade that took place back on Jan 07 ’25, which means that Pierre Kemula is holding shares at $254,219 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.8 for the gross margin
The net margin for CureVac N.V stands at 0.3. The total capital return value is set at 0.24. Equity return is now at value 28.12, with 21.36 for asset returns.
Based on CureVac N.V (CVAC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 2.61.
Currently, EBITDA for the company is 209.69 million with net debt to EBITDA at -2.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.54. The receivables turnover for the company is 16.27for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.28.
Conclusion
To sum up, CureVac N.V (CVAC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
